- Strong growth of Key Products and in most emerging markets was partly offset by the negative impact of pantoprazole's patent expiry in Europe, the economic downturn and adverse currency fluctuations.
- Total net turnover decreased 3.6% (-0.6% in local currencies and excluding one-time effects) to €3,228.0 million (FY/2008: €3,348.0 million). In the fourth quarter, total net turnover decreased 4.9% (-0.4% on a comparable basis) to €781.1 million (Q4/2008: €82
- Total net turnover increased 0.9% (3.2% in local currencies) to €820.0°million (Q3/08: €812.4°million)(1)
- Adjusted EBITDA decreased 3.1% (1.5% in local currencies) to €285.3°million (Q3/08: €294.4°million)(1)
- Pantoprazole sales resilient after loss of exclusivity. Newly-launched OTC variant performing strongly in Europe
- Roflumilast (Daxas®) submitted to FDA and agreement with Forest L
Modern, state-of-the-art production plant to be built in Yaroslavl region
Investment up to €75 million
Construction starts in 2010, plant opening in 2014